209 related articles for article (PubMed ID: 37152370)
21. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
Front Immunol; 2021; 12():676922. PubMed ID: 34335575
[TBL] [Abstract][Full Text] [Related]
22. A Pyroptosis-Related Gene Signature to Predict Patients' Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma.
Wang J; Huang Z; Lu H; Zhang R; Feng Q; He A
Comput Math Methods Med; 2022; 2022():1258480. PubMed ID: 35242200
[TBL] [Abstract][Full Text] [Related]
23. Identification of hepatocellular carcinoma-related subtypes and development of a prognostic model: a study based on ferritinophagy-related genes.
Wang G; Li J; Zhu L; Zhou Z; Ma Z; Zhang H; Yang Y; Niu Q; Wang X
Discov Oncol; 2023 Aug; 14(1):147. PubMed ID: 37555866
[TBL] [Abstract][Full Text] [Related]
24. A scoring model based on ferroptosis genes for prognosis and immunotherapy response prediction and tumor microenvironment evaluation in liver hepatocellular carcinoma.
Gao L; Xue J; Liu X; Cao L; Wang R; Lei L
Aging (Albany NY); 2021 Nov; 13(22):24866-24881. PubMed ID: 34839280
[TBL] [Abstract][Full Text] [Related]
25. Prognostic prediction using a gene signature developed based on exhausted T cells for liver cancer patients.
Zhou Y; Wu W; Cai W; Zhang D; Zhang W; Luo Y; Cai F; Shi Z
Heliyon; 2024 Mar; 10(6):e28156. PubMed ID: 38533068
[TBL] [Abstract][Full Text] [Related]
26. High Levels of DEAH-Box Helicases Relate to Poor Prognosis and Reduction of DHX9 Improves Radiosensitivity of Hepatocellular Carcinoma.
Chen X; Lin L; Chen G; Yan H; Li Z; Xiao M; He X; Zhang F; Zhang Y
Front Oncol; 2022; 12():900671. PubMed ID: 35814441
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis of diverse programmed cell death patterns in the prognosis, tumor microenvironment and drug sensitivity in hepatocellular carcinoma.
Yu Y; Lou Y; Zhu J; Wang X
Medicine (Baltimore); 2023 Dec; 102(48):e36239. PubMed ID: 38050240
[TBL] [Abstract][Full Text] [Related]
28. A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility.
Liu Y; Meng J; Ruan X; Wei F; Zhang F; Qin X
Sci Rep; 2024 Jan; 14(1):746. PubMed ID: 38185671
[TBL] [Abstract][Full Text] [Related]
29. Identification of a brand intratumor microbiome signature for predicting prognosis of hepatocellular carcinoma.
Song Y; Xiang Z; Lu Z; Su R; Shu W; Sui M; Wei X; Xu X
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11319-11332. PubMed ID: 37380815
[TBL] [Abstract][Full Text] [Related]
30. BUB1 predicts poor prognosis and immune status in liver hepatocellular carcinoma.
Qi W; Bai Y; Wang Y; Liu L; Zhang Y; Yu Y; Chen H
APMIS; 2022 Jul; 130(7):371-382. PubMed ID: 35255180
[TBL] [Abstract][Full Text] [Related]
31. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
32. Identification of cancer stem cell characteristics in liver hepatocellular carcinoma by WGCNA analysis of transcriptome stemness index.
Bai KH; He SY; Shu LL; Wang WD; Lin SY; Zhang QY; Li L; Cheng L; Dai YJ
Cancer Med; 2020 Jun; 9(12):4290-4298. PubMed ID: 32311840
[TBL] [Abstract][Full Text] [Related]
33. The Prognostic and Therapeutic Role of Histone Acetylation Modification in LIHC Development and Progression.
Gao J; Han S; Gu J; Wu C; Mu X
Medicina (Kaunas); 2023 Sep; 59(9):. PubMed ID: 37763801
[No Abstract] [Full Text] [Related]
34. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.
Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J
Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943
[TBL] [Abstract][Full Text] [Related]
35. Identification and analysis of necroptosis-associated signatures for prognostic and immune microenvironment evaluation in hepatocellular carcinoma.
Lu J; Yu C; Bao Q; Zhang X; Wang J
Front Immunol; 2022; 13():973649. PubMed ID: 36081504
[TBL] [Abstract][Full Text] [Related]
36. An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma.
Wu X; Jin B; Liu X; Mao Y; Wan X; Du S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10319-10333. PubMed ID: 37273105
[TBL] [Abstract][Full Text] [Related]
37. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
38. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
39. A prognostic exosome-related long non-coding RNAs risk model related to the immune microenvironment and therapeutic responses for patients with liver hepatocellular carcinoma.
Yue Y; Tao J; An D; Shi L
Heliyon; 2024 Jan; 10(2):e24462. PubMed ID: 38293480
[TBL] [Abstract][Full Text] [Related]
40. Analysis and Validation of Tyrosine Metabolism-related Prognostic Features for Liver Hepatocellular Carcinoma Therapy.
Cui Z; Liu C; Li H; Wang J; Li G
Curr Med Chem; 2024 Feb; ():. PubMed ID: 38415454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
